Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | UTHR |
---|---|---|
09:32 ET | 12329 | 272.15 |
09:34 ET | 500 | 272.9601 |
09:38 ET | 300 | 276.24 |
09:39 ET | 800 | 276.24 |
09:41 ET | 400 | 276.93 |
09:43 ET | 300 | 277.2 |
09:45 ET | 500 | 277.19 |
09:48 ET | 100 | 276.98 |
09:50 ET | 200 | 276.99 |
09:52 ET | 400 | 276.74 |
09:54 ET | 1204 | 275.775 |
09:56 ET | 400 | 276.46 |
09:57 ET | 800 | 276.04 |
09:59 ET | 347 | 276.5 |
10:01 ET | 700 | 276.16 |
10:06 ET | 1513 | 276.36 |
10:08 ET | 300 | 276.51 |
10:10 ET | 1774 | 276.51 |
10:12 ET | 400 | 276.97 |
10:14 ET | 400 | 276.96 |
10:15 ET | 200 | 276.555 |
10:17 ET | 2130 | 276.74 |
10:19 ET | 1357 | 276.39 |
10:21 ET | 200 | 276.345 |
10:24 ET | 200 | 276.38 |
10:26 ET | 300 | 276.375 |
10:28 ET | 341 | 276.0336 |
10:30 ET | 1044 | 275.97 |
10:32 ET | 100 | 276.11 |
10:33 ET | 653 | 276.28 |
10:35 ET | 329 | 276.67 |
10:39 ET | 784 | 277.47 |
10:44 ET | 900 | 278.34 |
10:46 ET | 300 | 278.21 |
10:48 ET | 983 | 278.64 |
10:50 ET | 1387 | 278.67 |
10:51 ET | 400 | 278.91 |
10:53 ET | 270 | 279.065 |
10:55 ET | 500 | 279.28 |
10:57 ET | 300 | 279.42 |
11:00 ET | 1143 | 279.18 |
11:02 ET | 100 | 279.47 |
11:04 ET | 857 | 279.48 |
11:06 ET | 515 | 279.48 |
11:09 ET | 500 | 279.24 |
11:11 ET | 3265 | 278.29 |
11:13 ET | 200 | 278.28 |
11:15 ET | 200 | 277.6881 |
11:18 ET | 200 | 277.68 |
11:20 ET | 100 | 277.79 |
11:26 ET | 588 | 277.98 |
11:27 ET | 1298 | 278.005 |
11:29 ET | 203 | 277.83 |
11:31 ET | 1412 | 278.19 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
United Therapeutics Corp | 12.2B | 13.2x | +8.22% |
Biomarin Pharmaceutical Inc | 14.3B | 74.5x | --- |
Medpace Holdings Inc | 12.0B | 41.1x | +35.10% |
Neurocrine Biosciences Inc | 13.6B | 37.2x | +62.04% |
Beigene Ltd | 16.0B | -20.9x | --- |
Exact Sciences Corp | 8.4B | -34.4x | --- |
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $12.2B |
---|---|
Revenue (TTM) | $2.5B |
Shares Outstanding | 44.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.49 |
EPS | $21.13 |
Book Value | $127.23 |
P/E Ratio | 13.2x |
Price/Sales (TTM) | 4.9 |
Price/Cash Flow (TTM) | 11.0x |
Operating Margin | 50.31% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.